ALISO VIEJO, Calif., Jan. 2 ValeantPharmaceuticals International (NYSE: VRX) today announced that effectiveDecember 31, 2008, the company completed its acquisition of Dow PharmaceuticalSciences, Inc., a privately held dermatology company that specializes in thedevelopment of topical products on a proprietary basis, as well as forpharmaceutical and biotechnology companies.
Valeant Pharmaceuticals International (NYSE: VRX) is a multinationalspecialty pharmaceutical company that develops, manufactures and markets abroad range of pharmaceutical products primarily in the areas of neurology anddermatology. More information about Valeant can be found athttp://www.valeant.com.(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO) Contact: Laurie W. Little Valeant Pharmaceuticals 949-461-6002
SOURCE Valeant Pharmaceuticals International